



## Newsletter - March 2025

---

Dear investigators,

Thanks to all your continued efforts, we have now reached **421 inclusions!**

We are very pleased with the progress so far and would like to encourage you to continue including patients in the trial.

- **Trial Protocol published**

Our trial protocol has been published in the European Stroke Journal, it can be accessed via the following link: <https://doi.org/10.1177/23969873251319941>

- **Payments April 2025**

Please complete Castor visits as these will be used to calculate the April 2025 payments. If you have any questions about which visits still need to be completed, please email [cases-trial@umcg.nl](mailto:cases-trial@umcg.nl)

- **Imaging**

We are currently collecting baseline and 24 hour imaging. Vouchers have been sent to centers that do not have XNAT. If there are any questions or problems regarding the sending of imaging, please let us know.

We appreciate your attention to these important points and look forward to seeing many of you in person at ESOC 2025 in Helsinki.

The CASES coordinating team

Dora, Louise, Femke, Anne, Nynke, Annemie, Robin, Paul and Maarten

---



**CASES TRIAL**     
WhatsApp-groep



## CASES Whatsapp group

Join our whatsapp group by scanning the QR code!  
Joining is voluntary.  
Get updates, ask questions, and share experiences and cases.

## Discharge form

Please check the patient's contact information. This can be done during the Informed Consent Procedure to make sure that the correct contact information is provided for the 3 months follow up.  
Please remember to fill in the discharge form via the website: <https://cases-trial.eu/CASES/ontslag.php>

## ASPECTS exclusion criteria

Recent trials on endovascular treatment in patients with ASPECTS  $<6$  have shown a low likelihood of favorable outcomes (mRS 0-2: 13-30%) and a potential increased risk of intracranial hemorrhage. In line with these findings and other trials (EASI-TOC, TITAN, PICASSO), the CASES protocol now excludes these patients. Before randomization, it is mandatory to review brain CT images and, if in doubt, verify the ASPECTS score with your interventionalist, documenting it in the source data (EPD, paper eCRF, etc.).



## ESOC 2025 Helsinki

**11<sup>th</sup> European  
Stroke Organisation  
Conference**21-23 May 2025  
Helsinki, Finland

eso-stroke.org/esoc2025



On Wednesday 21st of May 16:00 - 17:30 the CASES Investigator Meeting will take place at ESOC, together with Dutch ICH Surgery Trial (DIST) in meeting room 306, 3rd floor.

The meeting will be hybrid for those not able to attend.

Afterwards, the Dutch Strokeborrel and Belgium drinks will take place.

## Deferred Informed Consent

### Informed Consent Reminder for Investigators and Study Coordinators

It has come to our attention that there are quite a few patients who do not give consent.

We would like to remind all investigators and study coordinators of the following important procedure:

When initial deferred consent has been obtained from a participant's legal representative, it is crucial to also seek consent from the participant directly once their mental competence is restored. This may be at various stages of recovery, such as a few days before discharge, during rehabilitation, or at the 90-day follow-up consultation. If obtaining consent from the participant is not possible (e.g. poor functional recovery, loss-to-follow-up), it is essential to document this on the informed consent log.



For investigators in Belgium, you may continue using the existing "Information and Consent Form Participant/Legal Representative," with the participant now adding their signature.


For those in the Netherlands, please use the "Informatiebrief en toestemmingsformulier tweede instantie" to fulfill this requirement.

For more information regarding deferred informed consent and some helpful tips please visit:

[https://cases-trial.eu/DOC/SOP%20patient%20information%20and%20deferred%20consent%20\(CASES\).pdf](https://cases-trial.eu/DOC/SOP%20patient%20information%20and%20deferred%20consent%20(CASES).pdf)

## CASES inclusion progress





Documents such as the study protocol, information letters/informed consent forms and paper CRF worksheets can be found on the CASES website: [www.cases-trial.eu/](http://www.cases-trial.eu/)

If you have any questions don't hesitate to contact us via [cases-trial@umcg.nl](mailto:cases-trial@umcg.nl) or +31 6 5272 4593.

## Please inform us in case of:


- SAE's
- Crossover (with and without valid reason)
- Non-compliance with inclusion/exclusion criteria
- Failing to obtain or withdrawal of informed consent
- Protocol deviations regarding used stents/EVT devices, imaging not done in time window

For items listed above and any questions please contact us at: [cases-trial@umcg.nl](mailto:cases-trial@umcg.nl)  
or via telephone +31 6 5272 4593

## Frequently Asked Questions

Other Frequently Asked Questions can be found on our website: <https://cases-trial.eu/faq.html>

## The CASES study team



**Paul Nederkoorn**  
Principal Investigator



**Maarten Uyttenboogaart**  
Principal Investigator



**Robin Lemmens**  
Principal Investigator



**Femke Roelofs**  
CASES EXTENDED



**Theodora van Elk**  
Trial Coordinator



**Louise Maes**  
Trial Coordinator



**Anne van der Meij**  
Fellow Neurology



**Nynke Nicolaij**  
Research Nurse



**Annemie Devroye**  
Research Nurse

E-mail

[cases-trial@umcg.nl](mailto:cases-trial@umcg.nl)

Phone number

+31 6 5272 4593

Website

[www.cases-trial.eu/](http://www.cases-trial.eu/)